Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Neurotoxicity associated with deferoxamine therapy.

M H Freedman1, M Boyden, M Taylor

  • 1Department of Pediatrics, Hospital for Sick Children, University of Toronto, Canada.

Toxicology
|May 1, 1988
PubMed
Summary

High-dose deferoxamine (DFO) therapy for transfusion-dependent anemia can cause visual and auditory neurotoxicity. Lowering DFO dosage may prevent or reverse these adverse effects, ensuring safer treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Quantitative Phenotyping of Childhood Leukemia Identifies Variable and Invariable Cell Surface Antigens.

Leukemia & lymphoma·2016
Same author

In vitro cytotoxicity of deferoxamine on human marrow haematopoietic progenitors.

Toxicology in vitro : an international journal published in association with BIBRA·2010
Same author

Rh-D isoimmunization.

Canadian Medical Association journal·2010
Same author

Topological quantum computing with only one mobile quasiparticle.

Physical review letters·2006
Same author

Adenovirus-mediated p53 gene therapy in osteosarcoma cell lines: sensitization to cisplatin and doxorubicin.

Cancer gene therapy·2005
Same author

In vitro cytoprotective activity of squalene on a bone marrow versus neuroblastoma model of cisplatin-induced toxicity. implications in cancer chemotherapy.

European journal of cancer (Oxford, England : 1990)·2003

Area of Science:

  • Neuroscience
  • Hematology
  • Toxicology

Background:

  • Transfusion-dependent anemia requires iron chelation therapy.
  • Subcutaneous deferoxamine (DFO) is a common iron chelator.
  • Neurotoxicity is a potential adverse effect of DFO therapy.

Purpose of the Study:

  • To investigate the incidence and characteristics of visual and auditory neurotoxicity in patients receiving DFO.
  • To identify risk factors associated with DFO-induced neurotoxicity.
  • To evaluate the effect of DFO dosage adjustments on neurotoxicity.

Main Methods:

  • Retrospective analysis of 89 patients with transfusion-dependent anemia on DFO therapy.
  • Ophthalmologic, audiologic, and visual evoked potential (VEP) studies were performed.

Related Experiment Videos

  • Clinical data, including DFO dosage and serum ferritin levels, were analyzed.

    • Main Results:

    • 42 of 89 patients exhibited visual or auditory neurotoxicity.
    • Higher DFO doses (mg/kg) were associated with increased neurotoxicity.
    • Stopping or reducing DFO dosage improved or resolved neurotoxic symptoms in some patients.
    • Abnormal VEPs and audiograms were common, with some persisting after DFO cessation.

    Conclusions:

    • High-dose DFO is implicated in the pathogenesis of neurotoxicity.
    • Adjusting DFO dosage is crucial for managing and preventing neurotoxicity.
    • Serial monitoring and dose optimization can enable safer DFO administration.